Oramed Pharmaceuticals Commences Phase 2A Clinical Trials In Israel
Apr 17th 2008Drug InformationClinical Trials
Oramed Pharmaceuticals, Inc., (OTCBB: ORMP), a developer of oral delivery systems, commenced Phase 2A studies on its oral insulin capsule at the Hadassah Medical Center in Jerusalem, Israel yesterday. The Phase 2A trial is focused on assessing the safety and efficacy of the oral insulin capsule on 10 type 2 diabetes patients. This study is a continuation of the recently successfully completed Phase 1 studies in Israel.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
